Handok (002390) - Total Liabilities

Latest as of December 2025: ₩512.43 Billion KRW ≈ $347.27 Million USD

Based on the latest financial reports, Handok (002390) has total liabilities worth ₩512.43 Billion KRW (≈ $347.27 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Handok growing its equity to track the company's year-over-year net asset growth rate.

Handok - Total Liabilities Trend (2011–2025)

This chart illustrates how Handok's total liabilities have evolved over time, based on quarterly financial data. See 002390 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Handok Competitors by Total Liabilities

The table below lists competitors of Handok ranked by their total liabilities.

Company Country Total Liabilities
Guizhou Zhongyida Co Ltd
SHG:900906
China $908.87 Million
Nanoform Finland Plc
HE:NANOFH
Finland €12.56 Million
Iljin Diamond
KO:081000
Korea ₩68.98 Billion
Thai Rung Union Car Public Company Limited
BK:TRU
Thailand ฿442.46 Million
Flexible Solutions International Inc
NYSE MKT:FSI
USA $19.00 Million
Axis Corporation
TWO:6292
Taiwan NT$551.14 Million
Advanced Lithium Electrochemistry Cayman Co Ltd
TWO:5227
Taiwan NT$291.74 Million
Silvercrest Asset Management Group Inc
NASDAQ:SAMG
USA $81.72 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Handok's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002390 market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.77 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.65 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Handok's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Handok (2011–2025)

The table below shows the annual total liabilities of Handok from 2011 to 2025.

Year Total Liabilities Change
2025-12-31 ₩512.43 Billion
≈ $347.27 Million
+2.59%
2024-12-31 ₩499.49 Billion
≈ $338.50 Million
+11.07%
2023-12-31 ₩449.71 Billion
≈ $304.76 Million
-8.08%
2022-12-31 ₩489.25 Billion
≈ $331.56 Million
+6.92%
2021-12-31 ₩457.57 Billion
≈ $310.09 Million
+4.69%
2020-12-31 ₩437.08 Billion
≈ $296.20 Million
+8.01%
2019-12-31 ₩404.67 Billion
≈ $274.24 Million
+19.29%
2018-12-31 ₩339.24 Billion
≈ $229.90 Million
-2.69%
2017-12-31 ₩348.63 Billion
≈ $236.26 Million
+4.51%
2016-12-31 ₩333.60 Billion
≈ $226.08 Million
+47.04%
2015-12-31 ₩226.88 Billion
≈ $153.75 Million
+9.23%
2014-12-31 ₩207.71 Billion
≈ $140.76 Million
+15.88%
2013-12-31 ₩179.25 Billion
≈ $121.48 Million
+20.19%
2012-12-31 ₩149.14 Billion
≈ $101.07 Million
+14.83%
2011-12-31 ₩129.88 Billion
≈ $88.02 Million
--

About Handok

KO:002390 Korea Drug Manufacturers - Specialty & Generic
Market Cap
$78.88 Million
₩116.40 Billion KRW
Market Cap Rank
#20022 Global
#1013 in Korea
Share Price
₩8960.00
Change (1 day)
+1.13%
52-Week Range
₩6700.00 - ₩12360.00
All Time High
₩38942.94
About

HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food sup… Read more